Portfolio concentration
As of January 31, 2026 · N-PORT
Holdings
90
Top-10 weight
39.99%
Effective holdings
?
The number of equal-weight positions that would produce this portfolio's concentration (1 ÷ Herfindahl index). A 500-stock fund dominated by a few mega-caps might have only ~100 effective holdings.
40
Crowding
?
The value-weighted average number of funds that also own this fund's positions. High = consensus/crowded picks; low = holdings few other funds own.
558.4
Holdings
As of January 31, 2026 · N-PORT| # | Security | Ticker | Shares | Value | % of fund |
|---|---|---|---|---|---|
| 1 | GILEAD SCIENCES INC | — | 443,663 | $62.98M | 6.18% |
| 2 | AMGEN INC | — | 143,458 | $49.05M | 4.81% |
| 3 | VERTEX PHARMACEUTICALS INC | — | 102,150 | $48.00M | 4.71% |
| 4 | JAZZ PHARMA PLC | — | 283,073 | $46.56M | 4.57% |
| 5 | REGENERON PHARMACEUTICALS INC | — | 61,019 | $45.24M | 4.44% |
| 6 | ARGENX SE SPONSORED ADR | — | 48,962 | $41.15M | 4.04% |
| 7 | Franklin Institutional U.S. Government Money Market Fund | — | 35,318,834 | $35.32M | 3.47% |
| 8 | PRAXIS PRECISION MEDICINES INC | — | 104,696 | $32.87M | 3.23% |
| 9 | INSMED INC | — | 188,633 | $29.59M | 2.91% |
| 10 | Ascendis Pharma A/S | — | 129,742 | $29.33M | 2.88% |
| 11 | GUARDANT HEALTH INC | — | 248,985 | $28.39M | 2.79% |
| 12 | PTC THERAPEUTICS INC | — | 369,527 | $27.91M | 2.74% |
| 13 | TERNS PHARMACEUTICALS INC | — | 770,542 | $26.66M | 2.62% |
| 14 | ALNYLAM PHARMACEUTICALS INC | — | 66,908 | $22.62M | 2.22% |
| 15 | MIRUM PHARMACEUTICALS INC | — | 215,190 | $22.21M | 2.18% |
| 16 | REVOLUTION MEDICINES INC | — | 202,430 | $19.63M | 1.93% |
| 17 | MINERALYS THERAPEUTICS INC | — | 623,239 | $19.25M | 1.89% |
| 18 | ASTRAZENECA PLC SPONS ADR | — | 205,062 | $19.02M | 1.87% |
| 19 | NEUROCRINE BIOSCIENCES INC | — | 135,273 | $18.41M | 1.81% |
| 20 | Abivax SA SPONSORED ADS | ABVX US | 164,591 | $18.29M | 1.80% |
| 21 | EYEPOINT PHARMACEUTICALS INC | — | 1,269,215 | $17.16M | 1.68% |
| 22 | STRUCTURE THERAPEUTICS INC ADR | — | 192,930 | $17.06M | 1.68% |
| 23 | IONIS PHARMACEUTICALS INC | — | 205,400 | $16.98M | 1.67% |
| 24 | BRIDGEBIO PHARMA INC | — | 207,858 | $16.06M | 1.58% |
| 25 | LILLY ELI and CO | — | 14,071 | $14.59M | 1.43% |
| 26 | OLEMA PHARMACEUTICALS INC | — | 560,230 | $14.41M | 1.41% |
| 27 | ARCUTIS BIOTHERAPEUTICS INC | — | 505,651 | $12.83M | 1.26% |
| 28 | BENITEC BIOPHARMA INC | — | 995,152 | $12.12M | 1.19% |
| 29 | SYNDAX PHARMACEUTICALS INC | — | 579,788 | $11.78M | 1.16% |
| 30 | CG ONCOLOGY INC | — | 221,481 | $11.53M | 1.13% |
| 31 | DIANTHUS THERAPEUTICS INC | — | 203,063 | $10.84M | 1.06% |
| 32 | CENTESSA PHARMACEUTICALS LTD ADR | — | 424,429 | $10.43M | 1.02% |
| 33 | DYNE THERAPEUTICS INC | — | 519,232 | $9.29M | 0.91% |
| 34 | ARS PHARMACEUTICALS INC | — | 901,810 | $9.01M | 0.88% |
| 35 | Franklin Institutional US Government Money Market Fund | INFXX | 8,793,093 | $8.79M | 0.86% |
| 36 | ORUKA THERAPEUTICS INC | — | 249,964 | $8.56M | 0.84% |
| 37 | NUVALENT INC-A | — | 75,535 | $7.77M | 0.76% |
| 38 | SPYRE THERAPEUTICS INC | — | 220,000 | $7.04M | 0.69% |
| 39 | SOLENO THERAPEUTICS INC | — | 181,503 | $7.00M | 0.69% |
| 40 | ACHIEVE LIFE SCIENCES INC | — | 1,575,682 | $6.59M | 0.65% |
| 41 | BICARA THERAPEUTICS INC | — | 387,402 | $6.51M | 0.64% |
| 42 | AMYLYX PHARMACEUTICALS INC | — | 439,918 | $6.29M | 0.62% |
| 43 | UNIQURE N.V. | — | 270,640 | $6.15M | 0.60% |
| 44 | NEWAMSTERDAM PHARMA COMPANY NV | — | 187,726 | $5.84M | 0.57% |
| 45 | TANGO THERAPEUTICS INC | — | 491,884 | $5.71M | 0.56% |
| 46 | SPYRE THERAPEUTICS INC | — | 176,281 | $5.64M | 0.55% |
| 47 | INVENTIVA SA UNSPON ADR | IVA | 908,000 | $5.59M | 0.55% |
| 48 | CONTINEUM THERAPEUTICS INC CL A | — | 381,063 | $5.43M | 0.53% |
| 49 | APOGEE THERAPEUTICS INC | — | 82,737 | $5.42M | 0.53% |
| 50 | ORIC PHARMACEUTICALS INC | — | 524,519 | $5.38M | 0.53% |
1 / 2
Next ›
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.